Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) will likely be issuing its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $1.54 per share and revenue of $179.68 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Collegium Pharmaceutical Trading Down 2.8 %

Collegium Pharmaceutical stock traded down $0.85 during trading hours on Friday, hitting $28.91. The company had a trading volume of 74,294 shares, compared to its average volume of 371,011. Collegium Pharmaceutical has a 1 year low of $28.39 and a 1 year high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a market cap of $932.19 million, a P/E ratio of 12.45 and a beta of 0.82. The company has a 50-day moving average price of $31.00 and a two-hundred day moving average price of $33.72.

Insiders Place Their Bets

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.98% of the company's stock.

Analysts Set New Price Targets

COLL has been the subject of several analyst reports. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a report on Friday, January 10th. Piper Sandler lowered their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.